Lotus Pharmaceuticals, along with Alvogen US, Confirms ANDA filing and patent challenge for generic Revlimid®

Lotus Pharmaceuticals and Alvogen US today announced that Celgene filed a suit in the U.S. District Court of New Jersey. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Lotus’ ANDA for up to 30 months from the date the plaintiffs received notice of Lotus' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Read More

Highly experienced management team with a proven track record of achieving high growth and profitability.


News alert

Enter your email to sign up for news alerts